Dr. Willey, AccuGenomics Co-Founder and consultant, has been asked to speak at the SEQC-2 workshop with the presentation title of “Quality‐control solutions for targeted NGS in Cancer Diagnostics.” “Dr. Willey’s recent publications on standardizing the NGS RNAseq abundance measurements, and DNAseq quality assurance metrics provide needed quality controls for the application of NGS in the clinical setting”, says Dr. Morrison, CSO of AccuGenomics.
The FDA has led several quality control efforts to examine the latest tools for measuring gene activity, establish best practices for reproducibility across different technologies and laboratories, and evaluate the utility of those technologies in clinical and safety assessments. Dr. Willey has contributed to all the all the FDA’s MACQC studies. Links to these publications can be found on the FDA’s MicroArray/Sequencing Quality Control page.